Christopher Lieu, MD
Associate Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, Wake Forest University School of Medicine (2004)
Undergraduate School:
  • BS, University of North Carolina–Chapel Hill (NC) (2000)
Internship:
  • University of Colorado (University Hospital) Program (2005)
Residency:
  • University of Colorado (University Hospital) Program, Chief Resident, Internal Medicine (2008)
Fellowships:
  • University of Texas M D Anderson Cancer Center Program, Cancer / Oncology (2011)
Languages: English
Department: Medicine-Medical Oncology

Professional Titles

  • Associate Director for Clinical Research
  • co-Director, Gastrointestinal Medical Oncology

Recognition & Awards

  • Cancer Clinical Investigator Team Leadership Award (CCITLA), National Cancer Institute (NCI) (2017)
  • Leadership Development Program, American Society of Clinical Oncology (2017)
  • P30, National Cancer Institute (2017)
  • Rising Stars Award, Department of Medicine (2015)
  • Rational Targeting of the MAPK Pathway in Atypical RAS Mutant Colorectal Cancer in Next Generation Preclinical Models, The Hope Foundation’s SWOG Early Exploration and Development (SEED) Fund (2015)
  • K23, National Institutes of Health (2015)

Research Interests

I am a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. I am interested in resistance mechanisms to targeted therapy in GI cancers, and I was awarded the Conquer Cancer Foundation Career Development Award, NIH K23 grant, and a NIH R01 grant to study targeted therapies in colorectal cancer. I am also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.

Teaching

  • Associate Professor (2017)
    School of Medicine, Medicine

Publications

  • Chapman BC, Lai S, Friedrich T, Lieu CH, Moskalenko M, Olsen J, Herter W, Birnbaum EH, McCarter MD, Vogel JD. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy. Dis Colon Rectum. 2022 Jan 4. [Epub ahead of print] PubMed PMID: 34984995
  • Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, Messersmith W, Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. Front Oncol. 2021;11:614640. PubMed PMID: 33777751
  • Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021;12:607282. PubMed PMID: 33854497
  • Holowatyj AN, Perea J, Lieu CH. Gut instinct: a call to study the biology of early-onset colorectal cancer disparities. Nat Rev Cancer. 2021 Jun;21(6):339-340. PubMed PMID: 33833408
  • Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, Eckhardt SG, Messersmith WA, Pitts TM. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021;11:642328. PubMed PMID: 33869031
  • Zaborowski AM, Abdile A, Adamina M, Aigner F, d'Allens L, Allmer C, Álvarez A, Anula R, Andric M, Atallah S, Bach S, Bala M, Barussaud M, Bausys A, Bebington B, Beggs A, Bellolio F, Bennett MR, Berdinskikh A, Bevan V, Biondo S, Bislenghi G, Bludau M, Boutall A, Brouwer N, Brown C, Bruns C, Buchanan DD, Buchwald P, Burger JWA, Burlov N, Campanelli M, Capdepont M, Carvello M, Chew HH, Christoforidis D, Clark D, Climent M, Cologne KG, Contreras T, Croner R, Daniels IR, Dapri G, Davies J, Delrio P, Denost Q, Deutsch M, Dias A, D'Hoore A, Drozdov E, Duek D, Dunlop M, Dziki A, Edmundson A, Efetov S, El-Hussuna A, Elliot B, Emile S, Espin E, Evans M, Faes S, Faiz O, Fleming F, Foppa C, Fowler G, Frasson M, Figueiredo N, Forgan T, Frizelle F, Gadaev S, Gellona J, Glyn T, Gong J, Goran B, Greenwood E, Guren MG, Guillon S, Gutlic I, Hahnloser D, Hampel H, Hanly A, Hasegawa H, Iversen LH, Hill A, Hill J, Hoch J, Hoffmeister M, Hompes R, Hurtado L, Iaquinandi F, Imbrasaite U, Islam R, Jafari MD, Kanemitsu Y, Karachun A, Karimuddin AA, Keller DS, Kelly J, Kennelly R, Khrykov G, Kocian P, Koh C, Kok N, Knight KA, Knol J, Kontovounisios C, Korner H, Krivokapic Z, Kronberger I, Kroon HM, Kryzauskas M, Kural S, Kusters M, Lakkis Z, Lankov T, Larson D, Lázár G, Lee KY, Lee SH, Lefèvre JH, Lepisto A, Lieu C, Loi L, Lynch C, Maillou-Martinaud H, Maroli A, Martin S, Martling A, Matzel KE, Mayol J, McDermott F, Meurette G, Millan M, Mitteregger M, Moiseenko A, Monson JRT, Morarasu S, Moritani K, Möslein G, Munini M, Nahas C, Nahas S, Negoi I, Novikova A, Ocares M, Okabayashi K, Olkina A, Oñate-Ocaña L, Otero J, Ozen C, Pace U, São Julião GP, Panaiotti L, Panis Y, Papamichael D, Park J, Patel S, Patrón Uriburu JC, Pera M, Perez RO, Petrov A, Pfeffer F, Phang PT, Poskus T, Pringle H, Proud D, Raguz I, Rama N, Rasheed S, Raval MJ, Rega D, Reissfelder C, Reyes Meneses JC, Ris F, Riss S, Rodriguez-Zentner H, Roxburgh CS, Saklani A, Salido AJ, Sammour T, Saraste D, Schneider M, Seishima R... Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review. JAMA Surg. 2021 Sep 1;156(9):865-874. PubMed PMID: 34190968
  • Oba A, Wu YHA, Lieu CH, Meguid C, Colborn KL, Beaty L, Al-Musawi MH, Davis SL, Leal AD, Purcell T, King G, Wooten ES, Fujiwara Y, Goodman KA, Schefter T, Karam SD, Gleisner AL, Ahrendt S, Leong S, Messersmith WA, Schulick RD, Del Chiaro M. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Br J Surg. 2021 Aug 19;108(8):976-982. PubMed PMID: 34155509
  • Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Dec 22;:JCO2102538. [Epub ahead of print] PubMed PMID: 34936379
  • Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. J Gastrointest Oncol. 2021 Oct;12(5):2461-2474. PubMed PMID: 34790407
  • Patel SG, Murphy CC, Lieu CH, Hampel H. Early age onset colorectal cancer. Adv Cancer Res. 2021;151:1-37. PubMed PMID: 34148611
  • Han S, Kolb JM, Hosokawa P, Friedman C, Fox C, Scott FI, Lieu CH, Vajravelu RK, McCarter M, Murphy CC, Cook MB, Gleisner A, Falk GW, Katzka DA, Wani S. The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry. Am J Gastroenterol. 2021 Apr;116(4):811-815. PubMed PMID: 33982952
  • Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 Feb 1;39(4):285-294. PubMed PMID: 33356422
  • Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 Dec;17(12):757-770. PubMed PMID: 32632268
  • Moroney JW, Powderly J, Lieu CH, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 Nov 1;26(21):5631-5637. PubMed PMID: 32723836
  • Holowatyj AN, Washington KM, Salaria SN, Lieu CH, Idrees K, Eng C. Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. Gastroenterology. 2020 Oct;159(4):1605-1608. PubMed PMID: 32540351
  • Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2020 Dec 23;:JCO2001994. [Epub ahead of print] PubMed PMID: 33356422
  • Holowatyj A, Langston M, Han Y, Viskochil R, Perea J, Cao Y, Rogers C, Lieu CH, Moore JX. Community Health Behaviors and Geographic Variation in Early-Onset Colorectal Cancer Survival Among Women. Clinical and Translational Gastroenterology 2020; 11(12): e00266. Doi: 10.14309/ctg.0000000000000266 PMCID: PMC7678794
  • 40. Sandhu GS, Anders R, Blatchford P, Walde A, Leal A, King G, Leong S, Davis SL, Purcell WT, Goodman KA, Schefter T, Cowan M, Herter W, Meguid C, Weiss R, Marsh M, Brown M, Vogel J, Birnbaum E, Ahrendt S, Gleisner A, Schulick R, Del Chiaro M, McCarter M, Patel SG, Messersmith WA, Lieu CH. High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients. Colorectal Cancer 2020; 9(3): doi.org/10.2217/crc-2020-0012
  • Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res. 2019 Oct 1;25(19):5852-5858. PubMed PMID: 31243121
  • Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019 Aug 19;10(1):3722. PubMed PMID: 31427573
  • Dwyer AJ, Murphy CC, Boland CR, Garcia R, Hampel H, Limburg P, Lowery J, Zauber AG, Waring S, Worrall S, Perea J, Siegel R, Lee J, Molmenti C, Sears CL, Buckhaults P, Hayes R, Hussan H, de Miranda N, Palles C, Diaz L, Song M, Cercek A, Lieu CH, Patel SG, Karlitz JJ, Cao Y, Demb J, Blatchford P, Risendal B, Weltzien E, Wali A, Daschner P, Loomans-Kropp H, Flores R, Levell CL, Wehling K, Martin J, Pesmen C, Kuchar V, Soisson R, Davis A, Ahnen D. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer. Gastroenterology. 2019 Aug;157(2):280-288. PubMed PMID: 31095950
  • Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Jun 1;37(16):1436-1447. PubMed PMID: 30986117
  • Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019 Feb 8;7(1):37. PubMed PMID: 30736857
  • Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan;39:207-215. PubMed PMID: 31099678
  • Eckhardt SG, Lieu C. Is Precision Medicine an Oxymoron?. JAMA Oncol. 2018 Nov 8. [Epub ahead of print] PubMed PMID: 30419105
  • McCanney J, Winckworth-Prejsnar K, Schatz AA, Nardi EA, Dwyer AJ, Lieu C, Biru Y, Carlson RW. Addressing Survivorship in Cancer Care. J Natl Compr Canc Netw. 2018 Jul;16(7):801-806. PubMed PMID: 30006422
  • Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 Sep;100:35-45. PubMed PMID: 29936065
  • Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018 Sep 15;78(18):5398-5407. PubMed PMID: 30042150
  • Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist. 2018 Dec;23(12):1409-e140. PubMed PMID: 30139840
  • Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D. Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmol. 2018 Nov 1. [Epub ahead of print] PubMed PMID: 30383154
  • Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb 6;:JCO2016719807. [Epub ahead of print] PubMed PMID: 28165299
  • Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 May 1;35(13):1453-1486. PubMed PMID: 28165299
  • Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer. Am J Clin Pathol. 2017 Feb 3. [Epub ahead of print] PubMed PMID: 28165529
  • Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017 Mar;19(2):187-225. PubMed PMID: 28185757
  • Chapman BC, Hosokawa P, Henderson W, Paniccia A, Overbey DM, Messersmith W, Lieu C, Stiegmann GV, Schulick RD, Gajdos C. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. J Surg Oncol. 2017 Jun;115(8):1033-1044. PubMed PMID: 28334436
  • Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017 Sep 1;123(17):3402-3409. PubMed PMID: 28513823
  • Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 Sep;22(9):1024-e89. PubMed PMID: 28592615
  • Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas. 2017 Aug;46(7):904-912. PubMed PMID: 28697131
  • Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. PubMed PMID: 28817371
  • Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 Nov;5(11):942-949. PubMed PMID: 29038296
  • Meguid C, Schulick RD, Schefter TE, Lieu CH, Boniface M, Williams N, Vogel JD, Gajdos C, McCarter M, Edil BH. The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients. Ann Surg Oncol. 2016 Nov;23(12):3986-3990. PubMed PMID: 27342825
  • Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar;15(3):439-47. PubMed PMID: 26823490
  • Scott AJ, Lieu CH, Messersmith WA. Therapeutic Approaches to RAS Mutation. Cancer J. 2016 May-Jun;22(3):165-74. PubMed PMID: 27341593
  • Friedrich T, Leong S, Lieu CH. Beyond RAS and BRAF: a target rich disease that is ripe for picking. J Gastrointest Oncol. 2016 Oct;7(5):705-712. PubMed PMID: 27747084
  • Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C, Aide et Recherche en Cancérologie Digestive Foundation. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20;32(27):2975-84. PubMed PMID: 25002720
  • Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56. PubMed PMID: 24052618
  • Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8(10):e77117. PubMed PMID: 24143206
View All (47 Total) View Less

Professional Memberships

  • American Society of Clinical Oncology, Member
  • American Association for Cancer Research, Member
  • Rocky Mountain Oncology Society, Member
  • Arnold P. Gold Foundation, Member
  • Southwest Oncology Group, Member

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2007)
  • Medical Oncology, Board Certification (2011)
Conditions & Treatments
  • Cancers
  • Cancers - Colorectal Cancer
  • Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver)
  • Digestive System - Gastroenterology (Stomach, Bowel, General GI Problems)
  • Cancers - Biliary Cancer
  • Cancers - Cancer Medicine
  • Cancers - Cancer Prevention
  • Cancers - Pancreatic Cancer
  • Digestive System
Clinical Interests
I am interested in Gastrointestinal Cancers (Colorectal, Pancreatic, Gastric, Esophageal, Hepatocellular, Gallbladder, Bile Duct, Anal, Carcinoma of Unknown (Primary), Drug Development (Experimental Therapeutics) and Translational Research.

Care Philosophy
We strive to provide patient-focused, personalized, multi-disciplinary care for gastrointestinal (GI) cancers. Our specialized providers in Medical Oncology (chemotherapy and targeted therapies), Surgical Oncology, Radiation Oncology, Pathology, Molecular Pathology, Radiology, Interventional Radiology, Nuclear Medicine, Gastroenterology (both Hepatology and Interventional Endoscopy), Nutrition, and Integrative Medicine work together to achieve the best outcomes for our patients. We have cancer-specific multidisciplinary clinics in pancreas, colorectal, gastroesophageal, liver, and neuroendocrine cancers where patients can meet all of their specialty providers in a single clinic visit. Dr. Lieu joined the University of Colorado School of Medicine faculty in 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. Dr. Lieu completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010. Dr. Lieu currently serves as the co-Director of GI Medical Oncology at the University of Colorado Cancer Center, the Vice-Chair of the National Cancer Institute Colon Cancer Task Force, the FDA Oncologic Drugs Advisory Committee (ODAC), and the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.

Public Speaking
Yes

General Information

Medical Schools:
  • MD, Wake Forest University School of Medicine (2004)
Undergraduate Schools:
  • BS, University of North Carolina–Chapel Hill (NC) (2000)
Internships:
  • University of Colorado (University Hospital) Program (2005)
Residency Programs:
  • University of Colorado (University Hospital) Program, Chief Resident, Internal Medicine (2008)
Fellowships:
  • University of Texas M D Anderson Cancer Center Program, Cancer / Oncology (2011)
Languages: English
Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;